Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05556889
Other study ID # TJ2021S195
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 10, 2023
Est. completion date December 30, 2023

Study information

Verified date May 2023
Source Tongji Hospital
Contact Feng Gao
Phone 13971587381
Email fgao@tjh.tjmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. Efficacy of a modified auriculotemporal nerve blockade for patients undergoing supratentorial craniotomy 2. Safety of a modified auriculotemporal nerve blockade for patients undergoing supratentorial craniotomy


Description:

Scalp nerve block for supratentorial craniotomy patients can effectively reduce the consumption of perioperative analgesic drugs, avoid the occurrence of hypertension and tachycardia, relieve postoperative pain, improve postoperative recovery quality of patients. Scalp nerve block is safe and has fewer complications due to the small amount of local anesthetic. For auriculotemporal nerve block, temporary block of adjacent facial nerve is one of the most likely complications, with an incidence of 8.6%, and usually can be recovered within 24 hours, since the facial nerve was located in the anterior and lower part of the tragus, 1 cm deep in the skin. Therefore, improving nerve block methods and reducing the dosage of local anesthetics may reduce the risk of facial nerve block. The investigators proposed helix feet in front of the zygomatic arch as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood. The study intends to compare a modified auriculotemporal nerve block method with the traditional way, reflecting on perioperative hemodynamical fluctuation, postoperative analgesia effect and incidence of facial nerve paralysis. This will verify the safety and analgesic efficacy of the modified nerve block method proposed in this study, and then provide a basis for improving the quality of perioperative management during neurosurgery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 252
Est. completion date December 30, 2023
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Patients undergoing supratentorial craniotomy under general anesthesia; 2. 18-65 years old; 3. ASA I or II. Exclusion Criteria: 1. Emergency surgery; 2. Be allergic to ropivacaine; 3. Participating in other clinical investigation within 30 days; 4. Skin infection at the puncture site; 5. Patients taking analgesic drugs before surgery; 6. Persons addicted to alcohol or drugs; 7. Patients with severe liver and kidney dysfunction; 8. Patients with coagulation disorder; 9. Pregnant and lactating women; 10. Patients with consciousness disorder before surgery; 11. Those who have undergone neurosurgery within the last 6 months; 12. Patients who were unable to understand the NRS before surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
a modified auriculotemporal nerve blockade
Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
Traditional auriculotemporal nerve blockade
Traditional auriculotemporal nerve blockade

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tongji Hospital

Outcome

Type Measure Description Time frame Safety issue
Other operation time time from the time of surgery beginning until end of surgery during surgery
Other anesthesia time time from the time of anesthesia beginning until end of anesthesia during surgery
Other awakening time from the time of anesthesia end until time of patient awaken during surgery
Other PACU staying time from the time coming in PACU until the time coming out PACU during surgery
Other anesthetic dosage use dosage of anesthetic drug during operation during operation
Other urine volume urine volume during operation during operation
Other bleeding volume bleeding volume during operation during operation
Other maintenance infusion rate of remifentanil infusion rate of remifentanil for maintaining effective analgesic effect during operation during operation
Other the dosage of remedial painkillers (remifentanil) the dosage of remedial painkillers (remifentanil) during operation during operation
Other the dosage of remedial perdipine the dosage of remedial perdipine during operation during operation
Other the dosage of remedial esmolol the dosage of remedial perdipine during operation during operation
Other incidence of postoperative nausea in both two groups within 24 hours within 24 hours after supratentorial craniotomy, the investigators record the number of patients who suffer from postoperative nausea, and then calculate the incidence as: the number of patient suffering from postoperative nausea/the total number in corresponding group within 24 hours after supratentorial craniotomy
Other incidence of postoperative vomiting in both two groups within 24 hours within 24 hours after operation, the investigators record the number of patients who suffer from postoperative vomiting, and then calculate the incidence as: the number of patient suffering from postoperative vomiting/the total number in corresponding group within 24 hours after operation
Other incidence of hematoma at the block point in both two groups within 24 hours within 24 hours after operation, the investigators record the number of patients who suffer from hematoma at the block point, and then calculate the incidence as: the number of patient suffering from hematoma at the block point/the total number in corresponding group within 24 hours after operation
Other incidence of infection at the block point in both two groups within 24 hours within 24 hours after operation, the investigators record the number of patients who suffer from infection at the block point, and then calculate the incidence as: the number of patient suffering from infection at the block point/the total number in corresponding group within 24 hours after operation
Other incidence of local anesthetic toxicity in both two groups within 24 hours within 24 hours after operation, the investigators record the number of patients who suffer from local anesthetic toxicity, and then calculate the incidence as: the number of patient suffering from local anesthetic toxicity/the total number in corresponding group within 24 hours after operation
Other the time of initial administration of remedial antiemetics within 24 hours the time of initial administration of remedial antiemetics within 24 hours after operation within 24 hours after operation
Other the dosage of remedial antiemetics within 24 hours the dosage of remedial antiemetics within 24 hours after operation within 24 hours after operation
Primary numerical rating scale (NRS) score in both groups 2 hours after surgery 2 hours after supratentorial craniotomy, the participants subjectively determine the patient's pain scores using a 0 to 10 NRS (0 = no pain; 10 = unbearable pain), to evaluate the efficacy of the modified method. 2 hours after supratentorial craniotomy
Primary numerical rating scale (NRS) score in both groups 8 hours after surgery 8 hours after supratentorial craniotomy, the participants subjectively determine the patient's pain scores using a 0 to 10 NRS (0 = no pain; 10 = unbearable pain), to evaluate the efficacy of the modified method. 8 hours after supratentorial craniotomy
Primary numerical rating scale (NRS) score in both groups 24 hours after surgery 24 hours after supratentorial craniotomy, the participants subjectively determine the patient's pain scores using a 0 to 10 NRS (0 = no pain; 10 = unbearable pain), to evaluate the efficacy of the modified method. 24 hours after supratentorial craniotomy
Primary incidence of facial paralysis in both two groups within 24 hours after supratentorial craniotomy, the investigators evaluate facial nerve function of awakened participants (Diagnostic criteria for facial paralysis: unable to raise the eyebrows on the same side, unable to frown, unable to close eyes completely, or unable to smile due to facial paralysis on the same side), and record the number of patients who suffer from facial paralysis, and then calculate the incidence as: the number of patient suffering from facial paralysis/the total number in corresponding group within 24 hours after supratentorial craniotomy
Secondary mean arterial pressure (MAP) before anesthesia induction MAP before anesthesia induction before anesthesia induction
Secondary heart rate (HR) before anesthesia induction HR before anesthesia induction before anesthesia induction
Secondary MAP 3 minutes after tracheal intubation MAP 3 minutes after tracheal intubation 3 minutes after tracheal intubation
Secondary HR 3 minutes after tracheal intubation HR 3 minutes after tracheal intubation 3 minutes after tracheal intubation
Secondary MAP before nerve block MAP before nerve block before nerve block
Secondary HR before nerve block HR before nerve block before nerve block
Secondary MAP within 10 minutes after nerve block MAP within 10 minutes after nerve block within 10 minutes after nerve block
Secondary HR within 10 minutes after nerve block HR within 10 minutes after nerve block within 10 minutes after nerve block
Secondary MAP 1 minute after temporal region skin incision MAP 1 minute after temporal region skin incision 1 minute after temporal region skin incision
Secondary HR 1 minute after temporal region skin incision HR 1 minute after temporal region skin incision 1 minute after temporal region skin incision
Secondary MAP 2 minutes after temporal region skin incision MAP 2 minutes after temporal region skin incision 2 minutes after temporal region skin incision
Secondary HR 2 minutes after temporal region skin incision HR 2 minutes after temporal region skin incision 2 minutes after temporal region skin incision
Secondary MAP 3 minutes after temporal region skin incision MAP 3 minutes after temporal region skin incision 3 minutes after temporal region skin incision
Secondary HR 3 minutes after temporal region skin incision HR 3 minutes after temporal region skin incision 3 minutes after temporal region skin incision
Secondary MAP 4 minutes after temporal region skin incision MAP 4 minutes after temporal region skin incision 4 minutes after temporal region skin incision
Secondary HR 4 minutes after temporal region skin incision HR 4 minutes after temporal region skin incision 4 minutes after temporal region skin incision
Secondary MAP 5 minutes after temporal region skin incision MAP 5 minutes after temporal region skin incision 5 minutes after temporal region skin incision
Secondary HR 5 minutes after temporal region skin incision HR 5 minutes after temporal region skin incision 5 minutes after temporal region skin incision
Secondary MAP 10 minutes after temporal region skin incision MAP 10 minutes after temporal region skin incision 10 minutes after temporal region skin incision
Secondary HR 10 minutes after temporal region skin incision HR 10 minutes after temporal region skin incision 10 minutes after temporal region skin incision
Secondary MAP 20 minutes after temporal region skin incision MAP 20 minutes after temporal region skin incision 20 minutes after temporal region skin incision
Secondary HR 20 minutes after temporal region skin incision HR 20 minutes after temporal region skin incision 20 minutes after temporal region skin incision
Secondary MAP 30 minutes after temporal region skin incision MAP 30 minutes after temporal region skin incision 30 minutes after temporal region skin incision
Secondary HR 30 minutes after temporal region skin incision HR 30 minutes after temporal region skin incision 30 minutes after temporal region skin incision
Secondary MAP 40 minutes after temporal region skin incision MAP 40 minutes after temporal region skin incision 40 minutes after temporal region skin incision
Secondary HR 40 minutes after temporal region skin incision HR 40 minutes after temporal region skin incision 40 minutes after temporal region skin incision
Secondary MAP 50 minutes after temporal region skin incision MAP 50 minutes after temporal region skin incision 50 minutes after temporal region skin incision
Secondary HR 50 minutes after temporal region skin incision HR 50 minutes after temporal region skin incision 50 minutes after temporal region skin incision
Secondary MAP 1 hour after temporal region skin incision MAP 1 hour after temporal region skin incision 1 hour after temporal region skin incision
Secondary HR 1 hour after temporal region skin incision HR 1 hour after temporal region skin incision 1 hour after temporal region skin incision
Secondary MAP during surgery (at tracheal extubation) MAP during surgery (at tracheal extubation) during surgery (at tracheal extubation)
Secondary HR during surgery (at tracheal extubation) HR during surgery (at tracheal extubation) during surgery (at tracheal extubation)
See also
  Status Clinical Trial Phase
Recruiting NCT04994210 - Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL Phase 2
Terminated NCT05247957 - NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia N/A
Completed NCT04621123 - Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients Phase 2
Recruiting NCT05140616 - Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD Phase 1/Phase 2
Recruiting NCT05349552 - Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Completed NCT03820596 - Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL Phase 1/Phase 2
Recruiting NCT04446806 - Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Phase 4
Not yet recruiting NCT06244537 - Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer N/A
Recruiting NCT03455972 - Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT Phase 1/Phase 2
Completed NCT04785170 - Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals N/A
Recruiting NCT04677452 - Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM Phase 1
Completed NCT01305044 - The HEALS Project - Health Education and Active Living for Surviving Seniors Phase 2
Active, not recruiting NCT04646590 - A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 Phase 3
Recruiting NCT05021276 - Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD Phase 4
Not yet recruiting NCT05008666 - Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH Phase 2
Recruiting NCT06066840 - Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement Phase 4
Active, not recruiting NCT04852068 - A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells) Phase 3